AMLX

Amylyx Pharmaceuticals, Inc. [AMLX] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

AMLX Stock Summary

Top 10 Correlated ETFs

AMLX


Top 10 Correlated Stocks

AMLX


In the News

01:36 29 Mar 2024 AMLX

Amylyx's (AMLX) ALS Drug Fails Pivotal Study, Stock Down 82%

Following the study's failure, Amylyx (AMLX) is now uncertain whether to pull its orally administered ALS drug from the market. Management has voluntarily decided to pause all promotions of the drug.

08:00 29 Mar 2024 AMLX

Wall Street Predicted a Blockbuster. Now the Drug May Be Withdrawn.

Amylyx's ALS drug failed a late-stage trial, raising questions about the future of the drug and the company itself.

10:20 29 Mar 2024 AMLX

Amylyx's ALS Drug Fails Trial, Raising Questions About Company's Future

Relyvrio, which is sold under the name Albrioza in Canada, is Amylyx's only product.

07:10 29 Mar 2024 AMLX

Amylyx's ALS drug fails in late-stage confirmatory study

Amylyx Pharmaceuticals said on Friday its drug to treat a neurological disorder called ALS, or amyotrophic lateral sclerosis, failed to meet the main goal in a late-stage confirmatory study.

02:45 29 Mar 2024 AMLX

The Top 3 Biotech Stocks to Buy in March 2024

Investing in biotechnology (biotech) stocks is often thought of as being too risky for most investors. That's not necessarily the case.

06:30 29 Mar 2024 AMLX

7 Oversold Russell 2000 Stocks to Add to Your February Buy List

Investors may want to jump into oversold Russell 2000 stocks. For one, after a rough outing in 2023, smaller-cap stocks are starting to come back strong.

09:15 29 Mar 2024 AMLX

Amylyx Pharmaceuticals, Inc. (AMLX) Misses Q4 Earnings Estimates

Amylyx Pharmaceuticals, Inc. (AMLX) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.20 per share. This compares to loss of $0.65 per share a year ago.

12:58 29 Mar 2024 AMLX

Get Rich Quick With These 3 Biotech Stocks to Buy Now

I have always said it, and I keep my word regarding the biotechnology sector, since it is one of the largest and most important sectors. Not only is it vital for the financial markets, but for the quality of human life.

10:16 29 Mar 2024 AMLX

3 small-cap biotechs with potential breakthroughs in 2024

There's a reason that many biotech investors prefer to stick with large-cap stocks. Investing in small-cap biotech stocks is not for risk-averse investors.

12:40 29 Mar 2024 AMLX

AMLX vs. NBIX: Which Stock Should Value Investors Buy Now?

Investors with an interest in Medical - Drugs stocks have likely encountered both Amylyx Pharmaceuticals, Inc. (AMLX) and Neurocrine Biosciences (NBIX). But which of these two companies is the best option for those looking for undervalued stocks?

AMLX Financial details

Company Rating
Neutral
Market Cap
185.52M
Income
49.27M
Revenue
380.79M
Book val./share
6.43
Cash/share
5.51
Dividend
-
Dividend %
-
Employees
384
Optionable
No
Shortable
Yes
Earnings
10 May 2024
P/E
602.18
Forward P/E
-2.96
PEG
-49.55
P/S
3.76
P/B
2.64
P/C
0.52
P/FCF
-20.95
Quick Ratio
8.43
Current Ratio
9.52
Debt / Equity
0.01
LT Debt / Equity
0
-
-
EPS (TTM)
0.73
EPS next Y
-0.96
EPS next Q
-
EPS this Y
-121.53%
EPS next Y
-230.96%
EPS next 5Y
-188.43%
EPS last 5Y
NAN%
Revenue last 5Y
205.71%
Revenue Q/Q
5.61%
EPS Q/Q
-77.35%
-
-
-
-
SMA20
-84.04%
SMA50
-82.22%
SMA100
-83%
Inst Own
66.31%
Inst Trans
0.81%
ROA
-
ROE
-
ROC
-0.02%
Gross Margin
94%
Oper. Margin
-3%
Profit Margin
1%
Payout
-
Shs Outstand
67.78M
Shs Float
47.57M
-
-
-
-
Target Price
-
52W Range
2.7-31.77
52W High
-90.84%
52W Low
+42%
RSI
21.43
Rel Volume
0.65
Avg Volume
2.89M
Volume
1.87M
Perf Week
-3.07%
Perf Month
-81.15%
Perf Quarter
-84.02%
Perf Half Y
-84.9%
-
-
-
-
Beta
-0.657
-
-
Volatility
0.09%, 7.47%
Prev Close
-1.39%
Price
2.84
Change
2.9%

AMLX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.030.010.010.385.66
Net income per share
-0.33-0.98-1.59-3.390.73
Operating cash flow per share
-0.23-0.8-1.35-3.070.18
Free cash flow per share
-0.23-0.8-1.36-3.120.16
Cash per share
0.070.281.745.935.52
Book value per share
-0.56-1.45-2.745.826.45
Tangible book value per share
-0.56-1.45-2.745.826.45
Share holders equity per share
-0.56-1.45-2.745.826.45
Interest debt per share
0.360.0800.180.06
Market cap
823.13M830.34M997.75M2.16B989.69M
Enterprise value
834.97M818.89M947.56M2.11B823.73M
P/E ratio
-55.56-18.52-11.35-10.920.09
Price to sales ratio
577.231.28K3.5K97.232.6
POCF ratio
-77.02-22.63-13.34-12.0283.03
PFCF ratio
-77.02-22.53-13.28-11.8592.69
P/B Ratio
-32.46-12.44-6.66.352.28
PTB ratio
-32.46-12.44-6.66.352.28
EV to sales
585.531.26K3.32K94.72.16
Enterprise value over EBITDA
-62.41-21.15-11.46-10.4620.65
EV to operating cash flow
-78.13-22.31-12.67-11.769.11
EV to free cash flow
-78.13-22.22-12.61-11.5477.14
Earnings yield
-0.02-0.05-0.09-0.090.05
Free cash flow yield
-0.01-0.04-0.08-0.080.01
Debt to equity
-0.59-0.0200.020.01
Debt to assets
4.640.100.020.01
Net debt to EBITDA
-0.880.30.610.28-4.16
Current ratio
0.711.865.848.25.66
Interest coverage
-10.62-17.050-46.920
Income quality
0.780.870.850.910.24
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
2.1623.17136.615.720
Research and developement to revenue
8.3437.84154.534.20.34
Intangibles to total assets
00000
Capex to operating cash flow
0000.01-0.1
Capex to revenue
0-0.23-1.24-0.110
Capex to depreciation
0-151-6.79-5.19-1.14
Stock based compensation to revenue
0.080.37110.980.1
Graham number
2.025.659.921.0810.31
ROIC
1.40.630.55-0.570.08
Return on tangible assets
-4.6-3.18-0.83-0.510.1
Graham Net
-0.56-1.48-2.915.345.01
Working capital
-1.33M6.31M84.11M335.52M382.62M
Tangible asset value
-25.36M-66.73M-151.17M340.61M433.43M
Net current asset value
-25.38M-67.19M-155.27M331.29M380.64M
Invested capital
-0.59-0.0200.020.01
Average receivables
0007.65M27.68M
Average payables
02.9M10.5M32M34.34M
Average inventory
0004.88M24.05M
Days sales outstanding
000251.3138.39
Days payables outstanding
67.3353.62122.11K5.68K316.51
Days of inventory on hand
0001.19K549.82
Receivables turnover
0001.459.51
Payables turnover
5.426.8100.061.15
Inventory turnover
0000.310.66
ROE
0.580.670.58-0.580.11
Capex per share
00-0.01-0.04-0.02

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.331.011.461.521.61
Net income per share
-0.650.020.330.310.07
Operating cash flow per share
-0.76-0.070.13-0.080.2
Free cash flow per share
-0.77-0.080.12-0.080.2
Cash per share
5.34.885.315.275.51
Book value per share
5.214.985.756.216.43
Tangible book value per share
5.214.985.756.216.43
Share holders equity per share
5.214.985.756.216.43
Interest debt per share
0.140.030.080.070.06
Market cap
2.42B2.08B1.45B1.23B992.34M
Enterprise value
2.36B1.97B1.21B1.1B826.38M
P/E ratio
-14.15330.4416.4214.7752.44
Price to sales ratio
110.4529.1114.7712.029.15
POCF ratio
-48.64-409.93168.46-238.873.23
PFCF ratio
-48.04-390.67174.08-223.3775.21
P/B Ratio
7.15.93.752.952.29
PTB ratio
7.15.93.752.952.29
EV to sales
107.8827.5912.310.757.62
Enterprise value over EBITDA
-52.94-959.7558.9758.03369.74
EV to operating cash flow
-47.51-388.48140.29-213.5660.98
EV to free cash flow
-46.92-370.23144.97-199.7662.63
Earnings yield
-0.0200.020.020
Free cash flow yield
-0.0200.0100.01
Debt to equity
0.020.020.010.010.01
Debt to assets
0.020.010.010.010.01
Net debt to EBITDA
1.2652.98-11.84-6.86-74.26
Current ratio
8.27.866.679.525.66
Interest coverage
-14.130.59000
Income quality
1.16-3.220.39-0.252.86
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
2.570.620.440.470
Research and developement to revenue
1.040.340.30.290.41
Intangibles to total assets
00000
Capex to operating cash flow
0.010.05-0.030.07-0.03
Capex to revenue
-0.030000
Capex to depreciation
-3.41-1.23-0.99-1.18-1.18
Stock based compensation to revenue
0.280.110.10.10.09
Graham number
8.751.586.526.583.19
ROIC
-0.13-0.010.050.040
Return on tangible assets
-0.1100.050.040.01
Graham Net
4.784.384.885.124.99
Working capital
335.52M339.53M363.31M388.49M382.62M
Tangible asset value
340.61M352.65M386.37M418.4M433.43M
Net current asset value
331.29M333.74M360.17M385.93M380.64M
Invested capital
0.020.020.010.010.01
Average receivables
7.72M16.58M26.06M31.86M34.75M
Average payables
26.83M28.69M17.73M15.53M14.22M
Average inventory
5.17M11.42M18.97M28.62M35.35M
Days sales outstanding
62.9422.531.4125.8133.24
Days payables outstanding
1.49K183.48398.31109.89212.13
Days of inventory on hand
311.67222.74400.94558.39368.49
Receivables turnover
1.4342.873.492.71
Payables turnover
0.060.490.230.820.42
Inventory turnover
0.290.40.220.160.24
ROE
-0.1300.060.050.01
Capex per share
-0.0100-0.01-0.01

AMLX Frequently Asked Questions

What is Amylyx Pharmaceuticals, Inc. stock symbol ?

Amylyx Pharmaceuticals, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol AMLX

What is Amylyx Pharmaceuticals, Inc. stock quote today ?

Amylyx Pharmaceuticals, Inc. stock price is $2.84 today.

Is Amylyx Pharmaceuticals, Inc. stock public?

Yes, Amylyx Pharmaceuticals, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap